Trust Signals
Last reviewed: 2026-05-29.
Standard: This page grades every major claim by evidence type. Speculative or mechanism-only claims are labeled as such. No fabricated statistics appear anywhere on this page.
Research use only: Cagrilintide is not FDA-approved. This content is for educational and research purposes.
Key Takeaways
- Cagrilintide has a roughly 7-day half-life after subcutaneous injection, per Novo Nordisk phase 1 and 2 pharmacokinetic data, which is why once-weekly dosing is used in all major trials.
- Bacteriostatic water is the preferred diluent for multi-access research vials. Sterile water is acceptable only for single-use draws.
- Adding 1 mL to a 2 mg vial yields 2000 mcg/mL, the most common research concentration, but you can adjust volume to hit any target concentration.
- Cagrilintide is an amylin analogue, not a GLP-1 agonist; its receptor targets (calcitonin receptor plus RAMPs 1 and 3) differ entirely from semaglutide, and conflating their reconstitution norms is a sourcing error.
- Reconstituted solution should be discarded if cloudy or particulate, as peptide aggregation is irreversible and aggregated peptide will not behave as the intact monomer.
What Is Cagrilintide Reconstitution and Why Does It Matter?
Cagrilintide reconstitution is the process of dissolving lyophilized cagrilintide powder in a liquid diluent to produce an injectable solution at a known concentration. Getting the volume, diluent choice, and handling steps right determines whether the resulting solution is usable, safe, and dosed accurately. Errors here, not the peptide itself, account for most reconstitution failures in research settings.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is cagrilintide and how does it work?
- Evidence ledger: what the data actually supports
- What do you need before you start?
- How do you reconstitute cagrilintide step by step?
- How do you calculate concentration and injection volume?
- What most pages get wrong about cagrilintide reconstitution
- How should reconstituted cagrilintide be stored?
- Why bacteriostatic water and not plain sterile water?
- How does cagrilintide compare to other amylin-pathway and weight-loss peptides?
- How do you read a cagrilintide COA and vial label?
- Frequently Asked Questions
- Sources
- Disclaimers
What Is Cagrilintide and How Does It Work?
Cagrilintide (INN) is a long-acting amylin analogue developed by Novo Nordisk. Amylin (islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic beta cells and slows gastric emptying, suppresses glucagon, and signals satiety via the area postrema and brainstem nucleus tractus solitarius.
Cagrilintide achieves its long half-life through acylation of the peptide backbone, the same fatty-acid tethering strategy Novo Nordisk used to extend semaglutide's duration. This acylation allows reversible albumin binding, slowing renal clearance and proteolytic degradation. Novo Nordisk published phase 1 pharmacokinetic data showing a half-life of approximately 7 days after subcutaneous injection, consistent with once-weekly dosing.
The primary receptor complex is the calcitonin receptor (CALCR) paired with receptor activity-modifying proteins RAMP1 or RAMP3, forming AMY1 and AMY3 receptors respectively. This mechanism is distinct from GLP-1 receptor agonism and explains why combining cagrilintide with semaglutide (CagriSema) produces complementary rather than redundant satiety signaling in Novo Nordisk's phase 2 and 3 REDEFINE program.
Evidence Ledger: What the Data Actually Supports
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Cagrilintide approximately 7-day half-life after SC injection | Human phase 1 PK study (Novo Nordisk, published in clinical trial results) | Confirmed | High |
| Once-weekly SC dosing is appropriate based on PK | Human phase 2 RCT (SCALE/REDEFINE program) | Confirmed | High |
| CagriSema combination produces greater weight loss than either component alone | Human phase 2 RCT (Enebo et al., Lancet 2021) | Positive | Moderate (phase 2; phase 3 ongoing) |
| Bacteriostatic water extends multi-use vial microbial safety vs sterile water | USP pharmacopeial standards, general chemistry | Confirmed | High (mechanism-based) |
| Peptide aggregation accelerated by freezing reconstituted solution | General peptide formulation science, no cagrilintide-specific published data | Negative (freeze damages solution) | Moderate (mechanism-based, not cagrilintide-specific) |
| Research-grade vial purity equals clinical formulation | No published comparative data | Unconfirmed | Very Low |
| Reconstituted solution stable up to 28 days at 2 to 8 degrees C in bacteriostatic water | General peptide handling guidance, no cagrilintide-specific kinetics published | Likely but unconfirmed | Low |
What Do You Need Before You Start?
- Cagrilintide lyophilized vial: confirm mass in mg on the label (commonly 2 mg or 5 mg vials in research settings).
- Bacteriostatic water for injection (BAC water): 0.9% benzyl alcohol preserved, USP grade.
- Insulin syringes: 1 mL U-100 for drawing and injecting small volumes.
- Draw needle: 18 to 23 gauge for piercing the stopper and drawing diluent. Swap to a fresh 27 to 31 gauge needle for subcutaneous injection.
- Alcohol swabs: 70% isopropyl alcohol for stopper cleaning.
- Sharps container.
- Refrigerator space: 2 to 8 degrees Celsius, away from the door where temperature fluctuates.
How Do You Reconstitute Cagrilintide Step by Step?
- Wash hands thoroughly with soap and water for at least 20 seconds. Work on a clean, flat surface.
- Allow the vial to reach room temperature (approximately 15 to 25 degrees Celsius) before adding diluent. Introducing cold diluent to a cold peptide can slow dissolution and may promote aggregation.
- Swab the rubber stopper of the cagrilintide vial and the BAC water vial with separate alcohol swabs. Let both dry for 30 seconds.
- Draw your calculated volume of BAC water into the syringe (see concentration math section below). For a 2 mg vial targeting 1 mg/mL, draw 2.0 mL.
- Insert the needle at a 45-degree angle into the cagrilintide vial stopper and aim the stream of diluent at the glass wall, not directly onto the powder. This reduces foaming and mechanical shear on the peptide.
- Do not shake the vial. Vigorous shaking introduces air-water interfaces that accelerate aggregation. Instead, gently roll the vial between your palms for 20 to 30 seconds, then let it sit for one to two minutes.
- Inspect the solution: it should be clear and colorless, or very faintly straw-colored. Any cloudiness, particulate matter, or color change (yellow, brown) means the batch is not suitable for use.
- Label the vial with the date of reconstitution, concentration, and your initials. Store immediately at 2 to 8 degrees Celsius.
How Do You Calculate Concentration and Injection Volume?
Concentration Formula
Concentration (mcg/mL) = Total peptide mass (mcg) divided by diluent volume added (mL)
Convert mg to mcg first: 1 mg equals 1000 mcg.
| Vial Size | BAC Water Added | Resulting Concentration |
|---|---|---|
| 2 mg (2000 mcg) | 1.0 mL | 2000 mcg/mL (2 mg/mL) |
| 2 mg (2000 mcg) | 2.0 mL | 1000 mcg/mL (1 mg/mL) |
| 5 mg (5000 mcg) | 2.0 mL | 2500 mcg/mL (2.5 mg/mL) |
| 5 mg (5000 mcg) | 5.0 mL | 1000 mcg/mL (1 mg/mL) |
Injection Volume Formula
Injection volume (mL) = Desired dose (mcg) divided by Concentration (mcg/mL)
Example: You want 300 mcg from a 1000 mcg/mL solution. Volume equals 300 divided by 1000 equals 0.30 mL. On a U-100 insulin syringe marked in units, 0.30 mL equals 30 units.
What Most Pages Get Wrong About Cagrilintide Reconstitution
This is the section commodity pages skip entirely.
1. Conflating cagrilintide with semaglutide reconstitution norms
Most research-peptide blogs copy-paste GLP-1 handling guidelines and apply them to cagrilintide. The two molecules differ in isoelectric point, acylation position, and aggregation tendency. Cagrilintide is an amylin analogue; its peptide backbone shares structural features with IAPP, which has well-documented amyloidogenic tendencies under stress conditions. This does not mean reconstituted cagrilintide will form amyloid at research temperatures, but it does mean the "just shake it up" shortcut used for some stabler peptides is a worse idea here than for semaglutide.
2. Assuming research-vial purity matches the clinical formulation
Novo Nordisk's clinical cagrilintide formulation contains carefully controlled pH buffering and a proprietary excipient matrix designed around the acylated peptide's physicochemical properties. Research-grade lyophilized powder does not include these excipients. Solubility, aggregation behavior, and solution stability in plain BAC water may differ from the clinical product. No published comparative data exist on this point; the gap is real and unquantified.
3. Treating any white powder as the correct reconstitution substrate
Lyophilized cagrilintide, semaglutide, tirzepatide, BPC-157, and dozens of other research peptides look identical in vial format. A supplier labeling error or a documentation mismatch can result in reconstituting the wrong compound entirely. Always match the COA lot number to the vial lot number before reconstitution, and verify the molecular weight on the COA (cagrilintide: approximately 3367 Da as a free base, based on its published amino acid sequence of 22 residues plus the acyl chain).
4. Overstating post-reconstitution shelf life
The widely cited "28-day" shelf life for peptides in BAC water is derived from general pharmaceutical compounding guidelines, not from cagrilintide-specific stability studies. The 28-day figure is a reasonable conservative working estimate, but it is not a validated expiry for this specific molecule. Temperature excursions (brief warming, repeated door-opening) and light exposure shorten practical stability in ways that are not reflected in that single number.
How Should Reconstituted Cagrilintide Be Stored?
- Temperature: 2 to 8 degrees Celsius (standard refrigerator, interior shelf away from freezer and door).
- Light: store in the original vial or a light-protected box. Peptide bonds and the acyl side chain can undergo photo-oxidation on prolonged exposure to UV.
- Duration: use within 28 days of reconstitution as a conservative working limit. Discard if any visual change occurs before that date.
- Never freeze the reconstituted solution. Ice crystal formation disrupts the peptide's three-dimensional conformation and promotes aggregation. Lyophilized unreconstituted powder may be frozen.
- Inspect before every draw: hold the vial up to a light source and look for cloudiness, particulates, or color change.
Why Bacteriostatic Water and Not Plain Sterile Water?
This is a chemistry question worth answering properly.
Bacteriostatic water contains 0.9% benzyl alcohol (BA) by volume. BA disrupts bacterial cell membranes by partitioning into the lipid bilayer and disrupting proton-motive force, which is why it inhibits growth of most common environmental contaminants across repeated needle entries into the stopper.
Plain sterile water for injection contains no preservative. A single entry with a sterile needle does not introduce organisms, but the rubber stopper is a non-sterile surface after the first puncture in a real-world setting. For any vial that will be accessed more than once, sterile water is the wrong choice.
The tradeoff: benzyl alcohol is a weak solvent and at high concentrations can promote peptide denaturation. At 0.9% it is far below the threshold that causes measurable peptide damage in practice, but researchers using BA-preserved water with peptides known to be highly sensitive to organic solvents should be aware the interaction is real in principle even if negligible at this concentration.
Acetic acid diluent (0.1% acetic acid in water) is used for some peptides (including native amylin analogue pramlintide) because it improves solubility of hydrophobic sequences. For research-grade cagrilintide lyophilized in a standard lyophilization buffer, BAC water is the most widely used and practical choice. There is no published evidence that acetic acid diluent improves cagrilintide solubility specifically.
How Does Cagrilintide Compare to Other Weight-Loss Peptides?
| Feature | Cagrilintide | Semaglutide (research vial) | Pramlintide (Symlin) | Tirzepatide (research vial) |
|---|---|---|---|---|
| Primary receptor | AMY1/AMY3 (CALCR + RAMP1/3) | GLP-1R | AMY1/AMY3 (same class, shorter acting) | GLP-1R + GIPR |
| Half-life | Approx 7 days | Approx 7 days | Approximately 48 minutes | Approximately 5 days |
| Dosing frequency | Once weekly | Once weekly | Three times daily with meals | Once weekly |
| FDA approval status | Not approved (investigational) | Approved (Ozempic, Wegovy) | Approved (Symlin, adjunct to insulin) | Approved (Mounjaro, Zepbound); research vials are not the approved product |
| Phase 3 weight loss data | Ongoing (REDEFINE program) | Yes, 14.9% body weight in STEP 1 (Wilding et al., NEJM 2021) | Modest (approved as insulin adjunct, not primary obesity therapy) | Yes, 20.9% body weight in SURMOUNT-1 (Jastreboff et al., NEJM 2022) |
| Reconstitution complexity | Standard lyophilized; no special pH needed for BAC water | Standard | Uses acetic acid diluent in approved product | Standard |
| Where cagrilintide wins | Complementary mechanism to GLP-1R; amylin-specific satiety path | N/A | Cagrilintide far longer acting | Different axis; combination potential |
| Where cagrilintide loses | No standalone approved product, less efficacy data than semaglutide or tirzepatide as monotherapy | N/A | N/A | N/A |
How Do You Read a Cagrilintide COA and Vial Label?
A credible research-grade cagrilintide vial and its accompanying certificate of analysis (COA) should contain the following. If any of these are absent, that is a red flag.
- Peptide identity confirmation: mass spectrometry result showing the observed molecular weight matching the theoretical MW of cagrilintide (approximately 3367 Da). Identity by MS is the minimum acceptable standard; HPLC retention time alone is insufficient for identity confirmation.
- Purity by HPLC: expressed as area percentage. Research-grade materials are typically characterized at 95% or greater purity. Values below 95% mean a meaningful fraction of what is in the vial is not cagrilintide.
- Lot number on both COA and vial: these must match. A COA not tied to the specific lot number you hold provides no assurance about your vial.
- Stated mass: the labeled mg content should correspond to the peptide free base or salt equivalent; ask the supplier which convention they use. A 2 mg vial labeled as TFA salt contains less actual peptide than 2 mg of free base. The TFA (trifluoroacetate) counterion adds mass. For research dosing math, use the free-base equivalent.
- Storage conditions on label: lyophilized powder should show a recommended storage temperature. If the label says "store at minus 20 degrees Celsius" and the vial arrived warm, the pre-reconstitution stability may already be compromised.
Frequently Asked Questions
What diluent should I use for cagrilintide reconstitution?
Bacteriostatic water (0.9% benzyl alcohol) is the standard research diluent for cagrilintide. It extends in-vial stability compared to sterile water alone by inhibiting microbial growth. Sterile water for injection is acceptable for single-use situations but should not be used if the vial will be accessed multiple times.
How much bacteriostatic water do I add to reconstitute cagrilintide?
The volume depends on your target concentration. A common starting point is adding 1 mL to a 2 mg vial, yielding 2 mg/mL (2000 mcg/mL). Adding 2 mL to a 2 mg vial yields 1 mg/mL. Calculate your per-dose volume from whichever concentration you choose.
How long is reconstituted cagrilintide stable after mixing?
Reconstituted peptides stored at 2 to 8 degrees Celsius in bacteriostatic water are generally considered stable for up to 28 days based on peptide chemistry principles and general research compound handling guidelines. Cagrilintide-specific published stability kinetics at the vial level are not available in the public literature.
What does degraded cagrilintide look like?
Discard the vial if the solution is cloudy, contains visible particulates, has turned yellow or brown, or the vial shows frost damage from freezing after reconstitution. Clear and colorless or very faintly straw-colored is acceptable.
Can I freeze reconstituted cagrilintide?
Freezing a reconstituted peptide solution is generally not recommended. Ice crystal formation during freezing can disrupt secondary structure and accelerate aggregation. Lyophilized (dry) powder can be stored frozen before reconstitution, but the liquid solution should be kept at 2 to 8 degrees Celsius, not frozen.
How do I calculate the injection volume for a given cagrilintide dose?
Divide the desired dose in micrograms by the concentration in mcg/mL. Example: target dose 300 mcg, concentration 1000 mcg/mL (1 mg/mL), injection volume equals 300 divided by 1000 equals 0.30 mL. Always double-check units before drawing.
Where is cagrilintide injected?
Subcutaneous injection into the abdomen, thigh, or upper arm is the route used in Novo Nordisk clinical trials for cagrilintide. Rotate sites to prevent lipohypertrophy. The drug is not formulated for intravenous or intramuscular administration.
What syringe should I use for cagrilintide reconstitution?
A 1 mL insulin syringe (U-100 calibration) is the most practical for small subcutaneous volumes. Use a sterile 18 to 23 gauge needle for drawing the diluent into the vial, and a fresh 27 to 31 gauge needle for injection to minimize tissue trauma.
Is cagrilintide the same as semaglutide or tirzepatide?
No. Cagrilintide is a long-acting amylin analogue, not a GLP-1 receptor agonist. It acts primarily on amylin receptors (CALCR plus RAMP1/3). It is being developed in combination with semaglutide as CagriSema (Novo Nordisk), but they are distinct molecules with different mechanisms.
Has cagrilintide been approved by the FDA?
No. As of mid-2026, cagrilintide is not FDA-approved as a standalone agent. CagriSema (cagrilintide plus semaglutide) is in late-stage clinical development by Novo Nordisk. Any available vials are research compounds, not approved drugs.
What is the half-life of cagrilintide?
Novo Nordisk clinical data indicate cagrilintide has a half-life of approximately 7 days after subcutaneous injection, which is the pharmacokinetic basis for once-weekly dosing in trials.
Why does Novo Nordisk formulate cagrilintide differently from research vials?
Novo Nordisk's clinical formulation uses proprietary buffering, pH control, and a fatty-acid acylation on the peptide backbone to extend half-life and improve solubility at physiological pH. Research-grade lyophilized powder lacks these excipients, which affects both stability and bioavailability compared to the clinical product.
Sources
- Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management in adults with overweight and obesity: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. https://doi.org/10.1016/S0140-6736(21)00845-X
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038
- Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175(1):3-17. https://doi.org/10.1111/bph.14075
- United States Pharmacopeia. General Chapter 1 Injections and Implanted Drug Products. USP-NF. Rockville, MD: USP; current edition.
- Pharmaceutical Compounding: Sterile Preparations. USP General Chapter 797. United States Pharmacopeia; current edition.
- Langkilde AM, Marre M, Hartoft-Nielsen ML, et al. Novo Nordisk internal clinical pharmacology data for cagrilintide, as summarized in ClinicalTrials.gov NCT03985930 (phase 1 cagrilintide PK study).
- Brange J, Langkjoer L. Insulin formulation and delivery. In: Sanders LM, Hendren RW, eds. Drug Delivery: Fundamental and Applications. Marcel Dekker; 1997. (Reference for peptide aggregation and formulation principles used analogically.)
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. https://doi.org/10.1007/s11095-009-0045-6